Faculty, Staff and Student Publications

Publication Date

5-11-2024

Journal

Journal of Hematology & Oncology

Abstract

Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.

Keywords

Inotuzumab Ozogamicin, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Agents, Immunological, Adult, Antineoplastic Combined Chemotherapy Protocols, Antibody-drug conjugate, Clinical trials, Efficacy, Immunotherapy, Lymphoid diseases., Antibody-drug conjugate, Clinical trials, Efficacy, Lymphoid diseases, Immunotherapy

DOI

10.1186/s13045-024-01552-7

PMID

38734670

PMCID

PMC11088766

PubMedCentral® Posted Date

5-11-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.